SU11248: Genesis of a new cancer drug: The development of a promising RTK inhibitor.

Scientist

Volumn 19, Issue 7, 2005, Pages 17-18

  Schlessinger, Joseph ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 (5 FLUORO 1,2 DIHYDRO 2 OXO 3 INDOLYLIDENEMETHYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID (2 DIETHYLAMINOETHYL)AMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SU 11657; SU 5402; SUTENT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER; CLINICAL TRIAL; DNA SEQUENCE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MEDICAL RESEARCH; MOLECULAR CLONING; MYELOID LEUKEMIA; SHORT SURVEY; SIDE EFFECT;

EID: 18344391889     PISSN: 08903670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. D. Hanahan, R.A. Weinberg, "The hallmarks of cancer," Cell, 100:57-70, 2000.
2. A. Ullrich, J. Schlessinger. "Signal transduction by receptors with tyrosine kinase activity," Cell, 61:203-12, 1990.
3. P. Blume-Jensen, T. Hunter. "Oncogenic kinase signaling," Nature, 411:355-65, 2001.
4. J. Schlessinger, "Cell signaling by receptor tyrosine kinases," Cell, 103:193-200, 2000.
5. H. Umezawa et al., "Studies on a new epidermal growth factor-receptor kinase inhibitors, erbstatin, produced by MH435-hF3," J Antibiot (Tokyo), 39:170-3, 1986.
6. A. Levitzki, A. Gazit, "Tyrosine kinase inhibition: an approach to drug development." Science, 267:1782-8, 1995.
7. M. Mohammadi et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," Science, 276:955-60, 1997.
8. A.D. Laird et al., "SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors," Cancer Res, 60:4152-60, 2000.
9. B.J. Druker et al., "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome," N Engl J Med, 344:1038-42, 2001.
10. H. Kantarjian et al., "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia," N Engl J Med, 346:645-52, 2002.
11. N.P. Shah et al., "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia," Cancer Cell, 2:117-25, 2002.
12. H. Jhoti, "A new school for screening," Nat Biotechnol, 23:184-6, Feb. 23, 2005.